# A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

> **NCT06035393** · PHASE2 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 82 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** HRG2005 inhalation
- **DRUG:** Placebo to match HRG2005 inhalation
- **DRUG:** Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
- **DRUG:** Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

## Key facts

- **NCT ID:** NCT06035393
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-15
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-02-17
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** Sponsor's R\&D strategy adjusted.
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035393, "A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06035393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*